Novozymes sees opportunity and risk in accordance of Bayer and Monsanto

London-Novozymes, which already struggle against the consequences of low oil prices and agricultural products, are eagerly waiting to see what the acquisition of Monsanto for Bayer will mean for the Danish group''s ties with its main partner.
The President Peder Holk Nielsen said in an interview that the merger between Bayer and Monsanto could broaden the market for microbial crop inputs, known as inoculants, but added that the Union also brings uncertainty.
"Certainly, in the short term we all worry about the distraction that a purchase of 66 billion dollars can cause, and that''s one of the things we have in our array of risk," he told Reuters during visit to London.
"But we think the results we have created together with Monsanto are quite significant and, if the deal is completed, I think it would make a lot of sense to take it to the new company."
Nielse hasn''t had any discussion with Bayer on its strategic ties with Monsanto, BioAg Alliance, but he said he hopes to do that before the merger is completed. Novozymes depends on the Alliance, which covers the sale of Inoculants for increased growth and resume sales.
The purchase agreement of the American seed company Monsanto for Bayer''s German is the most emblematic in a wave of mergers in recent years agriculture. However, Monsanto''s shares are still traded well below the value of Bayer''s bid, reflecting concerns that the merger could stagnate for antitrust issues.